Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

Journal of the Canadian Urological Association

Volumn 7, Issue 2, 2013, Pages

  Niraula, Saroj ^a   Pond, Greg ^b   de Wit, Ronald ^c   Eisenberger, Mario ^d   Tannock, Ian F ^a   Joshua, Anthony M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875067038     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.267     Document Type: Article

References (47)

1. Hanigan MH, del Cruz BL, Shord SS, et al. Optimizing Chemotherapy: Concomitant Medication Lists. Clin Pharmacol Ther 2011;89:114-9.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
4. Lopez-Lazaro M. Digoxin. HIF-1, and cancer. Proc Natl Acad Sci U S A 2009;106:E26; author reply E27.
5. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105:19579-86.
6. Rybalchenko V, Prevarskaya N, Van Coppenolle F, et al. Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating. Mol Pharmacol 2001;59:1376-87.
7. Theyer G, Schirmbock M, Thalhammer T, et al. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993;150:1544-7.
8. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007;8:395-402.
9. Zakikhani M, Dowling RJ, Sonenberg N, et al. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008;1:369-75.
10. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
11. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a populationbased case-control study. Cancer Causes Control 2009;20:1617-22.
12. Yeh JY, Huang WJ, Kan SF, et al. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 2001;166:1937-42.
13. Frederiksen LJ, Siemens DR, Heaton JP, et al. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 2003;170:1003-7.
14. Siemens DR, Heaton JP, Adams MA, et al: Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009;74:878-83.
15. Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
16. Gottesman MM, Pastan I. Clinical trials of agents that reverse multidrug-resistance. J Clin Oncol 1989;7:409-11.
17. Choi SU, Lee CO, Kim KH, et al. Reversal of multidrug resistance by novel verapamil analogs in cancer cells. Anticancer Drugs 1998;9:157-65.
18. Royer I, Monsarrat B, Sonnier M, et al: Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56:58-65.
19. Weis M, Heeschen C, Glassford A, et al. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45.
20. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389-98.
21. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
22. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
23. Sooriakumaran P, Coley HM, Fox SB, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29:1483-8.
24. Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med 2005;11:403-7.
25. Maucher A, Kager M, von Angerer E. Evaluation of the antitumour activity of coumarin in prostate cancer models. J Cancer Res Clin Oncol 1993;119:150-4.
26. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53:2046-52.
27. Frei B, Lawson S. Vitamin C and cancer revisited. Proc Natl Acad Sci U S A 2008;105:11037-8.
28. Palozza P, Colangelo M, Simone R, et al: Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 2010;31:1813-21.
29. Jiang Q, Wong J, Ames BN. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms. Ann N Y Acad Sci 2004;1031:399-400.
30. Giovannucci E, Rimm EB, Liu Y, et al: A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002;94:391-8.
31. Jiang Q, Wong J, Fyrst H, et al. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci U S A 2004;101:17825-30.
32. Crispen PL, Uzzo RG, Golovine K, et al. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 2007;67:582-90.
33. Lindshield BL, Ford NA, Canene-Adams K, et al. Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. PLoS One 2010;5:e10423.
34. Malafa MP, Fokum FD, Andoh J, et al. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. Int J Cancer 2006;118:2441-7.
35. Lersch C, Gericke D, Classen M. Efficacy of low-molecular-weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature. Urol Int 1996;56:230-3.
36. Drago JR, Weed P, Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgeninsensitive prostate carcinoma. Anticancer Res 1984;4:171-2.
37. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995;154:247-50.
38. Peehl DM, Coram M, Khine H, et al. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol 2008;180:2206-11.
39. Feldman L, Wang Y, Rhim JS, et al: Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66:135-45.
40. Jeong JY, Hoxhaj G, Socha AL, et al. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 2009;7:1150-7.
41. Cervi D, Pak B, Venier NA, et al. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010;10:258.
42. Pei Z, Li H, Guo Y, et al. Sodium selenite inhibits the expression of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage. Int Immunopharmacol 2010;10:50-6.
43. Berggren M, Sittadjody S, Song Z, et al. Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutr Cancer 2009;61:322-31.
44. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009;2:484-95.
45. Lash TL, Cronin-Fenton D, Ahern TP, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010;49:305-12.
46. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
47. Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008;99:616-21.